Summary of Key Points
Gao Shanwen's death from lymphoma has sparked discussions about his treatment regimen, with the focus on two main issues: the timing of CAR-T therapy and the absence of vedotinib. The article analyzes that the timing of CAR-T therapy was appropriate (the experimental drug was only for patients with relapsed or refractory diseases; he was quickly enrolled after chemotherapy failed, and his connections likely accelerated the process). The decision not to use vedotinib was not a mistake, but rather due to insufficient evidence of its effectiveness against his rare type of lymphoma (AITL), highlighting the limitations in treatment options for rare diseases and the disparity in access to medical resources.
1. Was CAR-T used too late? In fact, the timing was appropriate and the speed was exceptional
CAR-T is still in the experimental phase and is not available for all patients upon diagnosis; it is only for those who have failed conventional treatments (such as chemotherapy). After chemotherapy in February, Gao's PET-CT results showed that some lymph nodes were unresponsive, indicating a relapsed or refractory condition, which met the criteria for enrolling in CAR-T trials.
More importantly, the speed of his CAR-T treatment was remarkable: T cells were extracted on April 28th, and the therapy was administered on May 20th—just three weeks later. Ordinary patients might have to wait months to get into such a trial, so the claim that CAR-T was used too late is unfounded.
2. Why was vedotinib not used? Insufficient evidence of effectiveness
Vedotinib is a targeted therapy: the antibody acts as a guide, delivering chemotherapy drugs directly to cancer cells with CD30 receptors. The FDA has approved it for first-line treatment of CD30-positive T-cell lymphomas, but for Gao's AITL, the data on its effectiveness are disappointing:
- In clinical trials, patients with AITL had a shorter progression-free survival period when using vedotinib compared to those receiving traditional chemotherapy;
- Five-year follow-up data showed no advantage in overall survival.
Therefore, doctors may have decided that it was not worth the risk.
3. The dilemma of treating rare diseases: limited treatment options
Gao's AITL is a rare type of lymphoma with only a few thousand cases nationwide each year. The main challenges for rare diseases are:
- Few patients mean insufficient samples for clinical trials, making it difficult to validate drug effectiveness;
- Pharmaceutical companies lack motivation to develop treatments for these diseases due to limited profit potential.
As a result, there are very few effective drugs available.
Doctors facing such patients have no standard approach and must choose from limited options, often with poor outcomes—Gao's case is a typical example: conventional chemotherapy was ineffective, and the effectiveness of experimental drugs was uncertain, leading to his unfortunate outcome.
4. Connections and status: The hidden barriers to medical resources
Gao's ability to quickly enroll in CAR-T trials and access top expert teams was due to his social status and connections. Ordinary patients may have to wait for a long time or never get the chance to receive such cutting-edge treatments, revealing the disparity in medical resources. Those with money and influence can access the most advanced treatments, while others face delays or shortages of standard therapies.
5. The neglected gap in drug development: Rare diseases are overlooked
The poor effectiveness of vedotinib for AITL reflects insufficient investment by pharmaceutical companies in rare disease research. With few patients and a small market, companies prefer to focus on more profitable conditions like lung cancer and diabetes. This leaves rare disease patients with limited treatment options, often relying on unproven drugs or participating in high-risk clinical trials.
Conclusion
Gao's story is not just a medical incident; it also highlights systemic issues in the treatment of rare diseases, such as delayed drug development, uneven distribution of medical resources, and limited treatment choices. For the general public, this highlights the importance of early screening for rare diseases, as early detection can greatly expand treatment options.